EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Barriers to publishing early phase clinical trials: the oncologists’ perspective

Merel J J Lucassen, Pedro Bergmann, Olga Husson iD, Udai Banerji iD, Bristi Basu iD, Ignacio Melero iD, Emiliano Calvo iD, Philippe A Cassier, Alexander Drilon iD, Peter C Fong, Elena Garralda iD, Anthony M Joshua und 12 weitere

The Oncologist · 04.04.2025 · 30 (4)

DOI: 10.1093/oncolo/oyaf042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 24.04.2025. Verfasst von Merel J J Lucassen und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands. Hauptthemen laut MEDLINE: Oncologists, Clinical Trials as Topic, Publishing, Medical Oncology. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Findings from early phase studies are not always placed in the public domain. This study aims to explore why many early phase clinical oncology studies are not published, as well as identify the potential barriers investigators encountered in the publication process.

Methods

Semi-structured interviews were conducted among investigators with experience in early phase clinical oncology studies. Interviews were analyzed using reflexive thematic analysis.

Results

Twenty-one investigators were interviewed. The majority worked in Europe (n = 13), while other investigators were based in North America (n = 4), Asia (n = 2) or Oceania (n = 2). We identified three reasons why investigators believed publishing early phase clinical trial results was important: (1) there is an ethical and moral responsibility; (2) there should be no loss of knowledge to society; and (3) there should be no waste of resources. Four main barriers in the publication process of early phase clinical trials were identified: (1) practical barriers (eg, an increased complexity of number of trials/trial sites), (2) insufficient resources (eg, money, time and human), (3) limited motivation (eg, limited intrinsic motivation of the investigator or limited prospect of return for the sponsor), and (4) inadequate collaboration (eg, different interests between industry partners and investigators). Finally, five major stakeholders were identified that can potentially contribute to improving the publication process: (1) journal editors, (2) sponsors, (3) investigators, (4) regulatory bodies, and (5) society. Investigator suggestions for improving this process, for each stakeholder, are presented.

Conclusions

This study highlights the barriers experienced in publishing early phase clinical trials. Recognizing and acknowledging these barriers is crucial to devise effective strategies to improve the publishing and public sharing of early phase clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OncologistsClinical Trials as TopicPublishingMedical OncologyHumans

Stichwörter der Autor:innen

ethicsmedical oncologypublicationqualitative research

Autor:innen und Institutionen

  • Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • The Royal Marsden NHS Foundation Trust, London SW3 6JJ, United Kingdom.
  • The Institute of Cancer Research, London SW7 3RP, United Kingdom.
  • University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 1TN, United Kingdom.
  • Clinica Universidad de Navarra, CIMA and CIBERONC, Pamplona 31008, Spain.
  • Nuffeld Department of Medicine, University of Oxford, Oxford OX3 7BN, United Kingdom.

ORCID-Profile: Olga Husson, Udai Banerji, Bristi Basu, Ignacio Melero, Emiliano Calvo, Alexander Drilon, Elena Garralda, Chia-Chi Lin, Juanita Lopez, Victor Moreno, Anna Minchom, Ruth Plummer, Sophie Postel-Vinay, Anna Spreafico, Toshio Shimizu, Christina Yap, Neeltje Steeghs

Förderung

  • NCI NIH HHS

Zitieren

APA

Lucassen, M. J. J., Bergmann, P., Husson, O., Banerji, U., Basu, B., Melero, I., Calvo, E., Cassier, P. A., Drilon, A., Fong, P. C., Garralda, E., Joshua, A. M., Lin, C. C., Lopez, J., Moreno, V., Minchom, A., Plummer, R., Postel-Vinay, S., Spreafico, A., …, & Steeghs, N. (2025). Barriers to publishing early phase clinical trials: the oncologists’ perspective. The Oncologist, 30(4). https://doi.org/10.1093/oncolo/oyaf042

Vancouver

Lucassen MJJ, Bergmann P, Husson O, Banerji U, Basu B, Melero I, et al. Barriers to publishing early phase clinical trials: the oncologists’ perspective. The Oncologist. 2025;30(4). doi:10.1093/oncolo/oyaf042

BibTeX
@article{Lucassen2025,
  author = {Lucassen, Merel J J and Bergmann, Pedro and Husson, Olga and Banerji, Udai and Basu, Bristi and Melero, Ignacio and Calvo, Emiliano and Cassier, Philippe A and Drilon, Alexander and Fong, Peter C and Garralda, Elena and Joshua, Anthony M and Lin, Chia-Chi and Lopez, Juanita and Moreno, Victor and Minchom, Anna and Plummer, Ruth and Postel-Vinay, Sophie and Spreafico, Anna and Shimizu, Toshio and Yap, Timothy A and Yap, Christina and De Bono, Johann S and Steeghs, Neeltje},
  title = {Barriers to publishing early phase clinical trials: the oncologists’ perspective},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {4},
  doi = {10.1093/oncolo/oyaf042}
}
Kostenlos starten →